Tilray, Inc. Stock price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 805M 1.09B | Sales 2025 * | 885M 1.2B | Capitalization | 1.43B 1.94B |
---|---|---|---|---|---|
Net income 2024 * | -155M -210M | Net income 2025 * | -72M -97.77M | EV / Sales 2024 * | 2.03 x |
Net Debt 2024 * | 209M 284M | Net Debt 2025 * | 174M 236M | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
-8.41
x | P/E ratio 2025 * |
-16.1
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.76% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 21-04-29 |
Carl Merton
DFI | Director of Finance/CFO | - | 21-04-29 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 21-04-29 |
David Clanachan
BRD | Director/Board Member | 62 | 21-04-29 |
Walter Robb
BRD | Director/Board Member | 70 | 21-04-29 |
1st Jan change | Capi. | |
---|---|---|
+30.83% | 687B | |
+30.73% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.08% | 211B | |
-6.36% | 208B | |
-3.89% | 203B | |
-3.72% | 157B |